Thermo Fisher Scientific develop two new antibody tests to expand COVID-19 portfolio

Written by Naamah Maundrell, Future Science Group

Thermo Fisher Scientific (MA, USA) have developed two new SARS-CoV-2 antibody tests termed: the Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test and the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG test. Both these tests detect COVID-19 antibodies and expand the company’s testing portfolio.

The OmniPATH COVID-19 Total Antibody ELISA test has been granted Emergency Use Authorization from the US FDA for qualitative detection of total SARS-CoV-2 antibodies including; IgM, IgA and IgG. The test was developed in association with the Mayo Clinic (MN, USA) and WuXi Diagnostics (Shanghai, China).

The Emergency Use Authorization is currently under review by the US FDA for the EliA SARS-CoV-2-Sp1 IgG test, which is designed for automated processing of up to 60 results per hour on the Thermo Scientific Phadia 250 instrument. The two new tests enable laboratories to use automated instruments already in place, which minimizes initial costs and reduces the time needed to begin testing.

Marc Casper, chairman, president and chief executive officer of Thermo Fisher Scientific, commented: “Thermo Fisher is committed to providing a range of innovative solutions, including new serology tests that complement our PCR-based tests. The addition of COVID-19 antibody tests to our broad portfolio further enables our support of the pandemic response on multiple fronts.”